Saros Therapeutics develops novel medicines to Improve Outcomes for patients with cancer. By harnessing the STING pathway with Saros' lipid nanoparticle technology, the limitations of prior STING agonists are significantly overcome. In combination with existing immunotherapies, this approach may enable a safe, effective immune response against tumors
Focusing on a novel therapeutic alternative to infection control in a surgical setting, Covira Surgical has developed a water-Soluble prescription medication that coats the GI Tract and prevents virulent bacteria from traveling to surgical wounds.
Through developing a first-in-class smartlens system that rapidly reduces intraocular pressure in glaucoma patients, bionode seeks to enhance glaucoma therapy and improve patient outcomes. The smartlens - called IOPTx - has proven success in clinical trials, reducing intraocular pressure in patients by 38%.
Still in the preclinical stage, Cadenza Bio is developing orally available small molecule drugs to promote remyelination and limit inflammation in patients with Multiple Mclerosis (MS). Their highly selective, non-steroidal agonists of Estrogen Receptor β (ERβ) harness the beneficial
neuroprotective and anti-inflammatory impacts of estrogen without risking feminization or proliferation associated with Estrogen Receptor α (ERα).
Our mission is to change the lives of cancer patients by transforming their journey. We have created a unique diagnostic platform designed specifically for specialty physician and oncologist offices. We have successfully brought together the speed and cost of point-of-care platforms combined with the accuracy and quality of core lab instruments. The platform will allow physicians to diagnose while their patient is in office eliminating extra office visits for the patient and accelerating the path to treatment.